The potential role of simeprevir for the treatment of hepatitis C

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44(1), 20–29 (2004).
  MedlineGoogle Scholar
• 2 World Health Organization. Hepatitis C. www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index2.html.
  Google Scholar
• 3 Smith DB, Bukh J, Kuiken C et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59, 318–327 (2014).•• Updates the HCV genotypes and their geographical distribution.
  MedlineGoogle Scholar
• 4 Pineda JA, Aguilar-Guisado M, Rivero A et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin. Infect. Dis. 49, 1274–1282 (2009).
  MedlineGoogle Scholar
• 5 Poordad F, McCone J Jr, Bacon BR et al. SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195–1206 (2011).
  Medline CASGoogle Scholar
• 6 Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with PEGinterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label randomised, multi-centre Phase II trial. Lancet 2376(9742), 705–716 (2010).•• Landmark study on the boceprevir a first generation protease inhibitor for treatment of HCV genotype 1.
  Google Scholar
• 7 Incivek™ (Telaprevir). US Prescribing Information. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed0e4f33-cf21-4fe3-918d-1d5b3a23eee4#section-8.1.
  Google Scholar
• 8 Hézode C, Forestier N, Dusheiko G et al. PROVE2 Study Team. Telaprevir and PEGinterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360(18), 1839–1850 (2009).
  Medline CASGoogle Scholar
• 9 Victrelis™ (Boceprevir). US Prescribing Information. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae879ebe-b620-4829-b6f8-74b58da1c771#section-7.1.
  Google Scholar
• 10 McHutchison JG, Manns MP, Muir AJ et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362(14), 1292–1303 (2010).
  Medline CASGoogle Scholar
• 11 Zeuzem S, Andreone P, Stanislas P et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364(25), 2417–2428 (2011).
  Medline CASGoogle Scholar
• 12 Bacon BR, Gordon SC, Lawitz E et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1207–1217 (2011).
  Medline CASGoogle Scholar
• 13 Lenz O, Vijgen L, Berke JM et al. Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). J. Hepatol. 58, 445–451 (2013).• Describes the effects of simeprevir across different HCV genotypes.
  Medline CASGoogle Scholar
• 14 Tsantrizos YS. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection. Curr. Opin. Investig. Drugs 10, 871–881 (2009).
  Medline CASGoogle Scholar
• 15 Koretz RL. Review: Telaprevir, boceprevir, simeprevir or sofosbuvir improves response in HCV type 1. Ann. Intern. Med. 161(10), JC11 (2014).
  MedlineGoogle Scholar
• 16 Fried MW, Buti M, Dore GJ et al. Once-daily simeprevir (TMC435) with PEGylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 58, 1918–1929 (2013).•• A dose-finding study on simeprevir.
  Medline CASGoogle Scholar
• 17 Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with PEGylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a Phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384, 403–413 (2014).•• Reports the results in naive patients and together with reference 2 are the basis for the registration of simeprevir.
  Medline CASGoogle Scholar
• 18 Manns M, Marcellin P, Poordad F et al. Simeprevir with PEGylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 384, 414–426 (2014).
  Medline CASGoogle Scholar
• 19 Manns MP, Fried MW, Zeuzem S et al. Simeprevir with PEGinterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. J. Viral Hepat. doi:10.1111/jvh.12346 (2014) (Epub ahead of print).
  Google Scholar
• 20 Forns X, Lawitz E, Zeuzem S et al. Simeprevir with PEGinterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a Phase 3 trial. Gastroenterology 146, 1669–1679 (2014).
  Medline CASGoogle Scholar
• 21 Reddy KR, Zeuzem S, Zoulim F et al. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with PEGylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. Presented at: 24th Conference of the Asian Pacific Association for the Study of the Liver. Brisbane, QLD, Australia, 12–15 March 2014.•• Reports the results in previously treated patients.
  Google Scholar
• 22 Dieterich D, Rockstroh JK, Orkin C et al. Simeprevir (TMC435) with PEGylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a Phase 3 study. Clin. Infect. Dis. 59, 1579–1587 (2014).
  Medline CASGoogle Scholar
• 23 Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 61(Suppl. 1), i47–i58 (2012).
  Medline CASGoogle Scholar
• 24 OLYSIO® (Simeprevir). Gains additional FDA approval as once-daily, all-oral interferon- and ribavirin-free treatment option in combination with sofosbuvir for adults with genotype 1 chronic hepatitis C infection (Press release) (2014). www.investor.jnj.com/releasedetail.cfm?ReleaseID=881192.
  Google Scholar
• 25 Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to PEGylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet doi:10.1016/S0140-6736(14)61036-61039 (2014) (Epub ahead of print).•• Reports the results of the interferon-free combination sofosbuvir and simeprevir in previously treated and naive patients with a different degrees of fibrosis patients.
  Google Scholar
• 26 Dieterich D, Bacon BR, Flamm SL et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 40, 220A (2014).
  Google Scholar
• 27 Jensen DM, O'Leary J, Pokros P et al. Safety and efficacy of Sofosbuvir-containing regimens for hepatitis C: real world experience in a diverse, longuitudinal observational cohort. Hepatology 40, 219A (2014).
  Google Scholar
• 28 Zeuzem S, Hezode C, Bronowicki JPP et al. LEAGUE-1 Study Team. Daclatasvir in combination with simeprevir ± ribavirin for hepatitis C virus genotype 1 infection. Presented at: 21st Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 March 2014 (Abstract 28LB).
  Google Scholar
• 29 Moreno C, Hezode C, Marcellin P et al. Once-daily simeprevir (TMC435) with PEGinterferon/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype-4 infected patients: SVR12 results of a Phase III trial. Presented at: The European Association for the Study of the Liver (EASL) Meeting. London, UK, 9–13 April 2014 (Poster #P1319).
  Google Scholar